Viridian Therapeutics, Inc.'s (VRDN) CEO Jonathan Violin on Q2 2022 Results - Earnings Call Transcript

Viridian Therapeutics, Inc. (NASDAQ:VRDN) Q2 2022 Earnings Conference Call August 15, 2022 8:00 AM ET

Company Participants

John Jordan - VP of IR
Jonathan Violin - President and CEO
Barrett Katz - Chief Medical Officer,
Raymond Douglas - Director of Thyroid Eye Disease
Kristian Humer - CFO and Chief Business Officer

Conference Call Participants

Chris Howerton - Jefferies
Thomas Smith - SVB Securities
Gavin Clark-Gartner - Evercore ISI
Rami Katkhuda - LifeSci Capital
Laura Chico - Wedbush Securities
Kalpit Patel - B. Riley Securities FBR
Jason Butler - JMP Securities
Trevor Allred - Oppenheimer
Michael Higgins - Ladenburg Thalmann

Operator

Greetings, and welcome to the Viridian Therapeutics Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions]. As a reminder, this conference is being recorded.

I would now like to turn the call over to John Jordan, Vice President of Investor Relations. Thank you. You may begin.

John Jordan

Thank you, Darryl. Good morning, everyone, and welcome to the Viridian conference call to discuss the initial clinical data for VRDN-001 in patients with Thyroid Eye Disease.

Before we begin, I would like to remind everyone that this conference call and webcast will contain forward-looking statements about the company. These statements are subject to risks and uncertainties that could cause actual results to differ. Please note that these forward-looking statements reflect our opinions only as of today. Except, as required by law, we specifically disclaim any obligation to update or revise these forward-looking statements, in light of new information or future events. Factors that could cause actual results or outcomes to differ materially from those expressed in or implied by such forward-looking statements are discussed in greater detail in our most recent filings on Form 10-K and 10-Q and other reports on file with the SEC.